LeonaBio, Inc.
LONADrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
LONA Earnings Report
EPS Est: $-1.90 | FQ end 2026-06
How LONA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATH-1017 | Phase 3 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in LeonaBio, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in LeonaBio, Inc.'s (LONA) pipeline across Phase 3. Its lead program is ATH-1017 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LeonaBio, Inc.'s next FDA catalyst?→
LeonaBio, Inc.'s (LONA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LONA biotech catalysts?→
Add LONA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LeonaBio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.